TWM
PACB icon

Titus Wealth Management’s Pacific Biosciences PACB Stock Holding History

Titus Wealth Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,261
Closed -$230K – 171
2021
Q4 		$230K Buy
11,261
+325
+3% +$7.84K 0.1% 153
2021
Q3 		$280K Buy
10,936
+15
+0.1% +$444 0.15% 118
2021
Q2 		$382K Buy
10,921
+970
+10% +$28.2K 0.21% 81
2021
Q1 		$331K Buy
9,951
+951
+11% +$33.3K 0.19% 87
2020
Q4 		$233K Buy
+9,000
New +$153K 0.14% 117

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Titus Wealth Management's PACB Position: Q1 2022 in Review

Titus Wealth Management sold out of Pacific Biosciences (PACB) in Q1 2022, closing a stake of 11,261 shares — an estimated $230K sold.

Titus Wealth Management first reported a position in PACB in Q4 2020 and held it in 5 quarters. The position peaked at $382K in Q2 2021. 250 funds tracked by Wall St. Rank hold PACB as of Q1 2022.

  • Titus Wealth Management reported no remaining Pacific Biosciences position as of Q1 2022 after selling out during the quarter.
  • Titus Wealth Management sold 11,261 Pacific Biosciences shares in Q1 2022, an estimated $230K.
  • Titus Wealth Management first reported a position in Pacific Biosciences in Q4 2020 and held it in 5 quarters.
  • Titus Wealth Management's Pacific Biosciences position peaked at $382K in Q2 2021.
  • 250 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2022.

Based on Titus Wealth Management's 13F filing for Q1 2022, filed 16 May 2022.